INGM
Fondazione Istituto Nazionale Genetica Molecolare
Mission
The decodification of the sequences of the human genome has opened a
great gap between the capacity of accumulating scientific information
and the possibility of translating these new discoveries into new
therapies or improved diagnostic means. Italy as all European countries
has an enormous need to optimize its research resources. Therefore,
more "translational" research and a greater capacity to create "collaboration networks" among the different national and international
research organizations. INGM comes to life with the aim of
strengthening Italian biomedical research in these two key points for
innovation.
INGM represents an opportunity for Italian biomedical research to constitute a technological platform (human immuno-proteomics) managed professionally and with strong connections with clinics so as to become an example of "translational" research. The success of the latter will soon translate scientific discoveries into improvement of health.
The presence among the founders of INGM of IRCCS Ospedale Maggiore of Milan facilitates the establishment of collaborations with the most important Italian IRCCS. As regards the collaboration with international institutes, we look for networks of common, equally shared programs characterized by high technological contents. In the private sector, the intent is to collaborate, on the basis of common interests, with leading Italian and international biotechnology companies, so as to create the bond between public and private research that represents the strength of technological innovation in the USA, but that has not been exploited to a great extent in Italy.
The initiative of the Ministry of Health for the creation of INGM underscores the need of Italian biomedical research to set up new structures so as to be competitive in the translation of basic research into technology and products capable of improving health. INGM will be an advanced research center , which will create a well-defined niche of activities in the field of human proteomics research. Through a logical and diversified network of public and private collaborations, this will lead to the identification of new therapeutic targets and to the development of new diagnostic means for neoplastic diseases and diseases with autoimmune etiology.
INGM represents an opportunity for Italian biomedical research to constitute a technological platform (human immuno-proteomics) managed professionally and with strong connections with clinics so as to become an example of "translational" research. The success of the latter will soon translate scientific discoveries into improvement of health.
The presence among the founders of INGM of IRCCS Ospedale Maggiore of Milan facilitates the establishment of collaborations with the most important Italian IRCCS. As regards the collaboration with international institutes, we look for networks of common, equally shared programs characterized by high technological contents. In the private sector, the intent is to collaborate, on the basis of common interests, with leading Italian and international biotechnology companies, so as to create the bond between public and private research that represents the strength of technological innovation in the USA, but that has not been exploited to a great extent in Italy.
The initiative of the Ministry of Health for the creation of INGM underscores the need of Italian biomedical research to set up new structures so as to be competitive in the translation of basic research into technology and products capable of improving health. INGM will be an advanced research center , which will create a well-defined niche of activities in the field of human proteomics research. Through a logical and diversified network of public and private collaborations, this will lead to the identification of new therapeutic targets and to the development of new diagnostic means for neoplastic diseases and diseases with autoimmune etiology.